MED8 and cancer: Compared with CRLs signature in other cancer types, such as five-CRLs signature (FOXD2-AS1, NRAV, MED8-AS1, WARS2-AS1 and MKLN1-AS) in hepatocellular carcinoma and three-CRLs signature (AC026401.3, FOXD2-AS1, and LASTR) in clear cell renal cell carcinoma [44,45], our study constructed a prognostic signature based on 10 CRLs (LINC02257, AC002066.1, NSMCE1-DT, AC010789.2, AL031985.3, FARSA-AS1, LINC01762, PDE9A-AS1, AC104964.3 and AC092375.2) for CC patients.